Insider Transactions in Q4 2023 at Olema Pharmaceuticals, Inc. (OLMA)
Insider Transaction List (Q4 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 29
2023
|
Cyrus Harmon |
SELL
Open market or private sale
|
Direct |
25,000
-1.35%
|
$325,000
$13.7 P/Share
|
|
Dec 12
2023
|
Shane William Charles Kovacs CH. OPERATING & FINANCIAL OFF. |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+2.25%
|
$70,000
$7.02 P/Share
|
|
Dec 11
2023
|
Naseem Zojwalla CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,900
+5.85%
|
$20,300
$7.02 P/Share
|
|
Dec 06
2023
|
Paradigm Biocapital Advisors LP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
100,000
+1.49%
|
$1,100,000
$11.6 P/Share
|
|
Dec 06
2023
|
Naseem Zojwalla CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
13,100
+23.04%
|
$91,700
$7.02 P/Share
|
|
Dec 05
2023
|
G. Walmsley Graham Director |
BUY
Open market or private purchase
|
Indirect |
131,870
+2.44%
|
$1,846,180
$14.26 P/Share
|
|
Nov 30
2023
|
Cyrus Harmon |
SELL
Open market or private sale
|
Direct |
25,000
-2.63%
|
$300,000
$12.57 P/Share
|
|
Nov 22
2023
|
Shane William Charles Kovacs CH. OPERATING & FINANCIAL OFF. |
SELL
Open market or private sale
|
Direct |
9,145
-2.11%
|
$118,885
$13.89 P/Share
|
|
Nov 22
2023
|
Sean Bohen PRESIDENT AND CEO |
SELL
Open market or private sale
|
Direct |
27,932
-16.16%
|
$363,116
$13.9 P/Share
|
|
Nov 22
2023
|
David C. Myles CH. DISCOV. & NON-CLIN DEV OFF |
SELL
Open market or private sale
|
Direct |
6,653
-1.15%
|
$86,489
$13.89 P/Share
|
|
Nov 22
2023
|
Naseem Zojwalla CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
7,095
-18.79%
|
$92,235
$13.89 P/Share
|
|
Nov 22
2023
|
Cyrus Harmon |
SELL
Open market or private sale
|
Direct |
3,989
-0.42%
|
$51,857
$13.9 P/Share
|
|
Nov 21
2023
|
Shane William Charles Kovacs CH. OPERATING & FINANCIAL OFF. |
SELL
Open market or private sale
|
Direct |
9,597
-1.08%
|
$143,955
$15.05 P/Share
|
|
Nov 21
2023
|
Sean Bohen PRESIDENT AND CEO |
SELL
Open market or private sale
|
Direct |
29,293
-7.34%
|
$439,395
$15.07 P/Share
|
|
Nov 21
2023
|
David C. Myles CH. DISCOV. & NON-CLIN DEV OFF |
SELL
Open market or private sale
|
Direct |
6,976
-0.59%
|
$104,640
$15.1 P/Share
|
|
Nov 21
2023
|
Naseem Zojwalla CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
7,461
-8.29%
|
$111,915
$15.08 P/Share
|
|
Nov 21
2023
|
Cyrus Harmon |
SELL
Open market or private sale
|
Direct |
4,192
-0.44%
|
$58,688
$14.86 P/Share
|
|
Nov 20
2023
|
Shane William Charles Kovacs CH. OPERATING & FINANCIAL OFF. |
BUY
Grant, award, or other acquisition
|
Direct |
36,750
+7.65%
|
-
|
|
Nov 20
2023
|
Sean Bohen PRESIDENT AND CEO |
BUY
Grant, award, or other acquisition
|
Direct |
110,250
+35.29%
|
-
|
|
Nov 20
2023
|
David C. Myles CH. DISCOV. & NON-CLIN DEV OFF |
BUY
Grant, award, or other acquisition
|
Direct |
26,250
+4.28%
|
-
|
|
Nov 20
2023
|
Naseem Zojwalla CHIEF MEDICAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
28,000
+38.24%
|
-
|
|
Nov 20
2023
|
Cyrus Harmon |
BUY
Grant, award, or other acquisition
|
Direct |
15,750
+1.62%
|
-
|
|
Nov 08
2023
|
David C. Myles CH. DISCOV. & NON-CLIN DEV OFF |
SELL
Open market or private sale
|
Direct |
200
-0.04%
|
$3,400
$17.61 P/Share
|
|
Nov 03
2023
|
David C. Myles CH. DISCOV. & NON-CLIN DEV OFF |
SELL
Open market or private sale
|
Direct |
541
-0.1%
|
$9,197
$17.51 P/Share
|
|
Nov 02
2023
|
David C. Myles CH. DISCOV. & NON-CLIN DEV OFF |
SELL
Open market or private sale
|
Direct |
3,332
-0.59%
|
$49,980
$15.36 P/Share
|
|
Nov 02
2023
|
Cyrus Harmon |
SELL
Open market or private sale
|
Direct |
5,000
-0.53%
|
$75,000
$15.64 P/Share
|
|
Nov 01
2023
|
David C. Myles CH. DISCOV. & NON-CLIN DEV OFF |
SELL
Open market or private sale
|
Direct |
6,668
-1.17%
|
$100,020
$15.02 P/Share
|
|
Oct 31
2023
|
Cyrus Harmon |
SELL
Open market or private sale
|
Direct |
25,000
-2.57%
|
$300,000
$12.05 P/Share
|